Enrique Poradosu
Förmögenhet: 18 M $ per 2026-05-31
Förmögenhet: 18 M $ per 2026-05-31
Dr. Enrique Poradosu is a Chief Scientific & Business Officer, Executive VP at Nuvectis Pharma, Inc. Dr. Poradosu was previously employed as a Senior VP-Business & Scientific Strategy by Stemline Therapeutics, Inc. and a Vice President-Business & Scientific Strategy by Keryx Biopharmaceuticals, Inc. He received his undergraduate degree from The Hebrew University of Jerusalem and a doctorate degree from The Hebrew University of Jerusalem.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
NUVECTIS PHARMA, INC. 6,81 % | 2026-04-13 | 1 806 319 ( 6,81 % ) | 18 M $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| NUVECTIS PHARMA, INC. | Grundare | 2020-07-27 |
| Företag | Position | Slut |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Företagsledare/Principal | 2020-12-01 |
| KERYX BIOPHARMACEUTICALS | Teknisk/Vetenskaplig/F&U Direktör | 2016-01-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel oncology therapeutics | Health Technology |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån